Cerotlizumab pegol - What role does this new TNF inhibitor have in the treatment of RA?

Nature Clinical Practice Rheumatology

Volumn 5, Issue 3, 2009, Pages 134-135

  Furst, Daniel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; METHOTREXATE; PLACEBO;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; NOTE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 62849119976     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum1004     Document Type: Note

References (5)

1. Furst DE et al. (2008) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67 (suppl 3): Iii2-iii25
2. Nesbitt A et al. (2007) Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 13: 1323-1332
3. Smolen JS et al. (2008) Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Active Rheumatoid Arthritis: The RAPID 2 Study. Ann Rheum Dis. [doi:10.1136/ard.2008.101659]
4. Keystone E et al. (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58: 3319-3329
5. Fleischmann R et al. (2008) Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: The FAST4WARD study. Ann Rheum Dis. [doi:10.1136/ard.2008.099291]